论文部分内容阅读
目的 探讨重组人类红细胞生成素 (r-HuEpo)对早产儿贫血的疗效。方法 将 3 5例胎龄 2 7～ 3 2周、出生体重 90 0～ 12 5 0g的早产儿贫血分成r-HuEpo治疗组和输血治疗组。r -HuEpo治疗组 2 0例 ,观察其外周血红细胞指标RBC ,Hb ,Hct和Ret的变化。输血组 15例。对比两组的输血量、献血员数和血液传播疾病发生情况。结果 r -HuEpo治疗 2周后外周血Ret和Hct明显增高 (P值分别为 <0 0 1和 <0 0 5 ) ,RBC和Hb亦有增高 (P >0 0 5 ) ,与输血治疗组比较 ,r-HuEpo治疗组所需输血量和献血员数均明显低于对照组 (P <0 0 1) ,输血治疗组有 2例发生丙肝。结论 r -HuEpo能改善早产儿贫血的外周血红细胞指标 ,部分代替输血 ,降低血液传播性疾病的风险
Objective To investigate the effect of recombinant human erythropoietin (r-HuEpo) on anemia in premature infants. Methods 35 cases of gestational age from 27 to 32 weeks, birth weight 90 0 to 125 g of anemia were divided into r-HuEpo treatment group and transfusion group. 20 cases of r-HuEpo treatment group were observed changes in peripheral blood red blood cells RBC, Hb, Hct and Ret. Blood transfusion group of 15 cases. Blood transfusion, blood donation and blood-borne diseases were compared between the two groups. Results The levels of Ret and Hct in peripheral blood were significantly increased after 2 weeks of r-HuEpo treatment (P <0 01 and <0 05, respectively) and RBC and Hb also increased (P 0 05) , blood transfusion volume and number of blood donors required for r-HuEpo treatment group were significantly lower than those of the control group (P <0.01). Two patients in the transfusion group had hepatitis C. Conclusion r-HuEpo can improve peripheral blood red blood cell markers of anemia in preterm infants, partially replace blood transfusion and reduce the risk of blood-borne diseases